At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06160 BEIGENE
Closed 05-27 16:09:08
180.600
-5.200
-2.80%
High184.000Low178.000Vol4.33M
Open183.800D1 Closing185.800Amplitude3.23%
Mkt Cap278.30BTradable Cap257.54BTotal Shares1.54B
T/O785.77MT/O Rate0.30%Tradable Shares1.43B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜BeiGene Declines 3.07% in Regular Trading, Trading at HK$182.5
Market Focus  ·  09:41
Movement Alert｜BeiGene Declines 3.07% in Regular Trading, Trading at HK$182.5
BUZZ-J&T Global Express leads gain in newcomers to Hang Seng Index
Reuters  ·  05-26 10:38
BUZZ-J&T Global Express leads gain in newcomers to Hang Seng Index
Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading
Stock News  ·  05-25 08:29
Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading
Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO
Deep News  ·  05-22
Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO
Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index
Deep News  ·  05-22
Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index
Movement Alert｜BeiGene Rises 3.48% in Regular Trading, Q1 Earnings Beat Expectations as Multiple Banks Raise Outlook
Market Focus  ·  05-21
Movement Alert｜BeiGene Rises 3.48% in Regular Trading, Q1 Earnings Beat Expectations as Multiple Banks Raise Outlook
Movement Alert｜BeiGene Rises 3.15% in Regular Trading, Q1 Earnings Beat Expectations as Major Banks Collectively Raise Outlook
Market Focus  ·  05-20
Movement Alert｜BeiGene Rises 3.15% in Regular Trading, Q1 Earnings Beat Expectations as Major Banks Collectively Raise Outlook
BEIGENE Shares Rise Nearly 3% on FDA Accelerated Approval for Sotoklara and Strong Q1 Earnings Beat
Stock News  ·  05-20
BEIGENE Shares Rise Nearly 3% on FDA Accelerated Approval for Sotoklara and Strong Q1 Earnings Beat
Major Financial Institutions Bullish on BEIGENE, Q1 Performance Confirms Long-Term Investment Value
Stock News  ·  05-19
Major Financial Institutions Bullish on BEIGENE, Q1 Performance Confirms Long-Term Investment Value
BEIGENE's BEQALZI™ Secures FDA Accelerated Approval as First and Only BCL2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma in the U.S.
Stock News  ·  05-14
BEIGENE's BEQALZI™ Secures FDA Accelerated Approval as First and Only BCL2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma in the U.S.
BEIGENE Announces Grant of Restricted Stock Units
Stock News  ·  05-13
BEIGENE Announces Grant of Restricted Stock Units
BeOne Announces US$7.94 Million RSU Grant Covering 0.02% of Share Capital
Bulletin Express  ·  05-13
BeOne Announces US$7.94 Million RSU Grant Covering 0.02% of Share Capital
BEIGENE Reports Q1 Profit Turnaround with 1.6 Billion Yuan Net Income
Stock News  ·  05-11
BEIGENE Reports Q1 Profit Turnaround with 1.6 Billion Yuan Net Income
Market Outlook: Hong Kong Stocks Rebound as Expected, Awaiting Multiple Catalysts
Stock News  ·  05-11
Market Outlook: Hong Kong Stocks Rebound as Expected, Awaiting Multiple Catalysts
CICC Maintains Outperform Rating on BEIGENE with HK$250 Target Price
Stock News  ·  05-08
CICC Maintains Outperform Rating on BEIGENE with HK$250 Target Price
Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players
Deep News  ·  05-07
Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players
BEIGENE's Q1 Net Profit Soars 399% Sequentially, Shares Jump 7% Post-Earnings
Deep News  ·  05-07
BEIGENE's Q1 Net Profit Soars 399% Sequentially, Shares Jump 7% Post-Earnings
Stock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge
Stock Track  ·  05-07
Stock Track | BEIGENE Soars 5.11% Intraday on Stellar Q1 Earnings with 178-Fold Net Profit Surge
BEIGENE Shares Surge Over 4% Post-Earnings on Stellar Q1 Performance
Stock News  ·  05-07
BEIGENE Shares Surge Over 4% Post-Earnings on Stellar Q1 Performance
Lithium Carbonate Spot Prices Surge Significantly; BEIGENE Reports 178-Fold Jump in Q1 Net Profit
Stock News  ·  05-07
Lithium Carbonate Spot Prices Surge Significantly; BEIGENE Reports 178-Fold Jump in Q1 Net Profit

Introduction

Company Name.
BEIGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Issue price:
--